Examkin

Soru

Zorluk: OrtaDiagnostic Workup and Test Sequencing

A 45-year-old woman is evaluated in the emergency department for severe, colicky right upper quadrant abdominal pain that radiates to her right scapula, accompanied by nausea. The pain began 6 hours ago after she ate a heavy meal. She is afebrile, and her vital signs are within normal limits. Physical examination reveals tenderness to palpation in the right upper quadrant without rebound or guarding. The Murphy sign is negative. Laboratory evaluation shows:

Total bilirubin: 2.1 mg/dL
Direct bilirubin: 1.5 mg/dL
Alkaline phosphatase: 250 U/L
Aspartate aminotransferase (AST): 110 U/L
Alanine aminotransferase (ALT): 125 U/L
Lipase: 45 U/L
Leukocyte count: 8,500/mm³

A right upper quadrant ultrasound demonstrates cholelithiasis without gallbladder wall thickening or pericholecystic fluid. The common bile duct measures 9 mm in diameter, but no stone is visualized within it. Which of the following is the most appropriate next step in the diagnostic workup of this patient?

  1. Magnetic resonance cholangiopancreatographyCevap
  2. B
    Endoscopic retrograde cholangiopancreatography
  3. C
    Computed tomography of the abdomen with intravenous contrast
  4. D
    Hepatobiliary iminodiacetic acid (HIDA) scan
  5. E
    Repeat right upper quadrant ultrasound in 48 hours

Cevap

Magnetic resonance cholangiopancreatography is the most appropriate next step because the patient's presentation places her at intermediate risk for choledocholithiasis, requiring non-invasive confirmation.
The correct option is Magnetic resonance cholangiopancreatography (MRCP). The patient's presentation of biliary colic, a dilated common bile duct (CBD) of 9 mm, and elevated liver function tests suggests choledocholithiasis. However, because she does not have high-risk features (such as clinical ascending cholangitis, a directly visualized CBD stone on ultrasound, or a total bilirubin greater than 4.0 mg/dL), her risk is classified as intermediate (10-50%). For intermediate-risk patients, current guidelines recommend non-invasive evaluation of the biliary tree with MRCP or endoscopic ultrasound (EUS) to confirm the diagnosis before proceeding to invasive procedures.

Adım Adım Çözüm

1
Evaluate the clinical, sonographic, and laboratory findings.
The patient has symptomatic cholelithiasis, a dilated common bile duct (9 mm), and mildly elevated liver function tests including bilirubin, but lacks ascending cholangitis or a bilirubin level over 4.0 mg/dL.
Accurate interpretation of these initial baseline investigations is necessary to stratify the patient's risk for a common bile duct stone.
2
Stratify the risk of choledocholithiasis according to established guidelines.
The combination of abnormal liver biochemistries and a dilated common bile duct (without high-risk predictors) categorizes the patient as having an intermediate probability (10% to 50%) of choledocholithiasis.
Risk stratification determines whether the patient should proceed directly to invasive therapeutic testing, non-invasive confirmatory imaging, or surgical intervention.
3
Select the guideline-indicated diagnostic test based on the risk category.
The correct test is a non-invasive confirmatory study, such as magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS).
This confirms the presence of a stone before subjecting an intermediate-risk patient to the procedural risks of an invasive procedure like ERCP.

Anahtar Kavram

Patients with an intermediate risk for choledocholithiasis (abnormal liver function tests and/or dilated common bile duct on ultrasound) should undergo non-invasive confirmatory testing with magnetic resonance cholangiopancreatography (MRCP) or endoscopic ultrasound (EUS) prior to invasive interventions.
Bu soruyu puanla

Konular

Diagnostic Workup and Test Sequencing

Bu konudan daha fazla soru